<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03058458</url>
  </required_header>
  <id_info>
    <org_study_id>C1104-001</org_study_id>
    <nct_id>NCT03058458</nct_id>
  </id_info>
  <brief_title>A First Time in Human Study of PIN201104 in Healthy Volunteers and Patients With Asthma</brief_title>
  <official_title>A First-time-in-human, Randomised, Double-blind, Placebo-controlled, Parallel-group Study in Healthy Volunteers and Patients With Asthma to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending and Repeat Doses of PIN201104</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peptinnovate</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peptinnovate</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability and pharmacokinetics of
      different single and repeat doses of PIN201104 in healthy volunteers and in patients with
      asthma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with TEAEs and number of events will be summarised by treatment</measure>
    <time_frame>21 days</time_frame>
    <description>Treatment Emergent Adverse Events after single and multiple dose administration will be collected at baseline and repeated until study completion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically significant abnormal haematology variables will be summarised by treatment.</measure>
    <time_frame>14 days</time_frame>
    <description>Haemoglobin, haematocrit, MCV, MCH, MCHC, RBC, WBC and differentials will be collected at baseline and after single and multiple dose administration and repeated until Day 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically significant abnormal clinical chemistry variables will be summarised by treatment.</measure>
    <time_frame>14 days</time_frame>
    <description>Creatinine, glucose, triglycerides, urea, uric acid, bilirubin, cholesterol, sodium, potassium, alkaline phosphatase, AST, ALT and GGT will be collected at baseline and after single and multiple dose administration and repeated until Day 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically significant abnormal electrocardiogram variables will be summarised by treatment.</measure>
    <time_frame>14 days</time_frame>
    <description>RR-interval, PR (PQ)-interval, QRS-duration, QT-interval, QTcB, QTcF and heart rate will be collected at baseline and after single and multiple dose administration and repeated until Day 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically significant abnormal vital sign variables will be summarised by treatment.</measure>
    <time_frame>14 days</time_frame>
    <description>Blood pressure, pulse rate, oral body temperature and respiration rate will be collected at baseline and after single and multiple dose administration and repeated until Day 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of PIN201104: The maximum observed plasma concentration (Cmax)</measure>
    <time_frame>24 hours</time_frame>
    <description>Cmax will be calculated after single and multiple IV dosing and single SC dosing of PIN201104</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of PIN201104: The time to reach Cmax (Tmax)</measure>
    <time_frame>24 hours</time_frame>
    <description>Tmax will be calculated after single and multiple IV dosing and single SC dosing of PIN201104</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of PIN201104: Apparent terminal elimination half life in plasma (t1/2)</measure>
    <time_frame>24 hours</time_frame>
    <description>t1/2 will be calculated after single and multiple IV dosing and single SC dosing of PIN201104</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of PIN201104: Area under the curve from time zero to the last quantifiable concentration of PIN201104 (AUC0-t)</measure>
    <time_frame>24 hours</time_frame>
    <description>AUC0-t will be calculated after single and multiple IV dosing and single SC dosing of PIN201104</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of PIN201104: Apparent plasma clearance of PIN201104 (CL/F)</measure>
    <time_frame>24 hours</time_frame>
    <description>CL/F will be calculated after single and multiple IV dosing and single SC dosing of PIN201104</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of PIN201104: Apparent volume of distribution (Vz/F)</measure>
    <time_frame>24 hours</time_frame>
    <description>Vz/F will be calculated after single and multiple IV dosing and single SC dosing of PIN201104</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>SAD PIN201104 in Healthy Volunteers (HV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PIN201104 or placebo IV administration, single dose, 10 dose cohorts</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Repeat dose PIN201104 in HV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PIN201104 or placebo IV administration, 3 doses on single day, 1 cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose PIN201104 in asthma patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PIN201104 or placebo IV administration, single dose, 2 cohorts</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single SC dose in HV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PIN201104 or placebo SC administration, single dose, 1 cohort</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PIN201104</intervention_name>
    <description>IV or SC administration</description>
    <arm_group_label>SAD PIN201104 in Healthy Volunteers (HV)</arm_group_label>
    <arm_group_label>Repeat dose PIN201104 in HV</arm_group_label>
    <arm_group_label>Single dose PIN201104 in asthma patients</arm_group_label>
    <arm_group_label>Single SC dose in HV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IV or SC administration</description>
    <arm_group_label>SAD PIN201104 in Healthy Volunteers (HV)</arm_group_label>
    <arm_group_label>Repeat dose PIN201104 in HV</arm_group_label>
    <arm_group_label>Single dose PIN201104 in asthma patients</arm_group_label>
    <arm_group_label>Single SC dose in HV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female subjects of non-childbearing potential age 18 to 65 years of
             age, and in good health as determined by medical history, physical examination, vital
             signs, electrocardiogram, and laboratory tests.

          -  Written informed consent must be obtained before any assessment is performed.

          -  Able to communicate well with the Investigator/designee.

        Exclusion Criteria:

          -  Any known reaction to study drug or components

          -  concurrent or recent infection or clinically significant conditions that may place
             subject at risk or interference with absorption, distribution or excretion of drugs

          -  No QTcF interval ≥450 milliseconds, no QRS complex ≥120 milliseconds, at Screening

          -  Positive test results for hepatitis B surface antigen (HBsAg), hepatitis C virus
             antibodies (HCVAb) or human immunodeficiency virus (HIV) 1 and/or -2 antibodies at
             Screening.

          -  Excessive use of caffeine-containing beverages

          -  Urinary cotinine level indicative of smoking or history or regular use of tobacco- or
             nicotine containing products within 6 months before screening.

          -  History of regular alcohol consumption within 6 months of screening 10.

          -  Positive screen for drugs-of-abuse or cotinine.

          -  Blood donation in excess of 500mL within 3 months.

          -  Participation in another study with an experimental drug within 3 months of first IMP
             administration.

          -  Exposure to more than 4 new chemical entities within 12 months before the first IMP
             administration.

          -  Ongoing rhinitis that requires treatment.

          -  Use of live vaccine 28 days before dosing with study drug until telephone follow-up
             and use of killed vaccine 14 days before dosing with study drug until telephone
             follow-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muna Albayaty, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parexel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Harrow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2017</study_first_submitted>
  <study_first_submitted_qc>February 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

